Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Withdrawn Phase 1 Interventional

Reirradiation With Concurrent Paclitaxel for Breast Cancer

NCT02058667
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel+Initial Radiation+Boost
Radiation
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

NCT00600275
View directory record Official record
Conditions
Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions
BGT226
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 22, 2026, 5:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

NCT05130801
View directory record Official record
Conditions
Breast Cancer
Interventions
pHLIP® ICG NIRF imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Montvale, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Breast Cancer Screening in Chinese Immigrants

NCT05089292
View directory record Official record
Conditions
Screening Mammogram
Interventions
Narrative breast health education
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 22, 2026, 5:08 AM EDT
Withdrawn No phase listed Observational

Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment

NCT05005936
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Ultrasonography
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 22, 2026, 5:08 AM EDT
Completed No phase listed Observational

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
assessment of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
3,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
451
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

NCT02536339
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Pertuzumab, Trastuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 2 Interventional

Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer

NCT00084539
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation therapy
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

Acupuncture for Chronic Lymphedema

NCT01706081
View directory record Official record
Conditions
Breast Cancer With Chronic Lymphedema
Interventions
Acupuncture, Wait-list
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Treatment of Breast Cancer

NCT00254592
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Carboplatin, Nab-paclitaxel, GM-CSF, Trastuzumab, Bevacizumab
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy in Treating Patients With Breast Cancer

NCT00012129
View directory record Official record
Conditions
Breast Cancer
Interventions
liposomal annamycin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 1 Interventional

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT03685331
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions
Palbociclib, Olaparib, Fulvestrant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 22, 2026, 5:08 AM EDT
Not listed Phase 3 Interventional

Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer

NCT00025688
View directory record Official record
Conditions
Breast Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
25
States / cities
Springdale, Arkansas • Monterey, California • Pomona, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 22, 2026, 5:08 AM EDT
Terminated Phase 1 Interventional

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

NCT04060342
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma
Interventions
GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
Drug
Lead sponsor
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 22, 2026, 5:08 AM EDT
Terminated Phase 1 Interventional

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT01233505
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
veliparib, capecitabine, oxaliplatin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Results available

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT00656305
View directory record Official record
Conditions
Bone Metastases, Multiple Myeloma
Interventions
ExAblate MRfFUS, Sham
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 100 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
La Jolla, California • Stanford, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 5:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

NCT02345772
View directory record Official record
Conditions
HER2-positive Breast Cancer, ER-positive Breast Cancer
Interventions
fulvestrant 500 mg, Docetaxel, Trastuzumab (H, 8mg/kg, Pertuzumab (P, 840 mg
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Results available

Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy

NCT01340495
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Proton Radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional

Integrated Intervention for Breast Cancer Survivors With Diabetes

NCT05092477
View directory record Official record
Conditions
Diabetes, Breast Cancer
Interventions
Integrated Intervention for Breast Cancer Survivors with Diabetes, Attention Control
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • New Hyde Park, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lymphedema Progression Screening Using MRI

NCT02611557
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Manual lymphatic drainage therapy
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 22, 2026, 5:08 AM EDT
Recruiting No phase listed Observational

Oncoplastic Surgery Outcomes Database

NCT07597837
View directory record Official record
Conditions
Breast Cancer
Interventions
Oncoplastic Breast Surgery
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2045
U.S. locations
2
States / cities
Boston, Massachusetts • Melrose, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

NCT00373256
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sunitinib, paclitaxel, bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
241
States / cities
Bessemer, Alabama • Birmingham, Alabama • Daphne, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Not applicable Interventional Results available

Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery

NCT03202472
View directory record Official record
Conditions
Breast Neoplasm, Lesion
Interventions
Implanted Medical Device, Mammography, Questionnaire Administration, Radiofrequency (RFID) -Guided Localization, Ultrasonography
Device · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 22, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

NCT00393939
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sunitinib malate, Taxotere
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Berkely, California • Shreveport, Louisiana • Beaumont, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 22, 2026, 5:08 AM EDT